RA1HA
Resimac Premier Series 2020-2
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cl A2 Frn Mat 07-Jun-2051 Min Cons $5Ht Nc
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RA1HA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RA1HA
N/A
RA1HA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in RA1HA also invest in...
Want more shares? Try these...
Race Oncology Ltd. is a precision oncology company, which engages in the discovery and development of the phase 2/3 cancer drug called Zantrene. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The firm is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The firm also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
📊 Share price
$1.51 AUD
R3D Resources Ltd. engages in the provision of investor relations and digital media solutions. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-12-17. The Company’s principal activity is focused on developing Chillagoe Region of far north Queensland. Its projects include Bulimba Project, Tartana Copper and Zinc Project, Zeehan Zinc Slag Project, Bellevue Copper-Gold and Dry River Project, Dimbulah Copper Porphyry Project, Nightflower Silver Project, Mt Hess Copper-Gold Project and Amber Creek Molybdenum-Tin-Tungsten Project. The company has six exploration permits in the Bulimba project, which covers over 1250 square kilometers. Tartana Copper and Zinc Project is located approximately 150 kilometers (km) west of Cairns and 40 km northwest of Chillagoe along the Burke Development Road. Its subsidiary, Intec Zeehan Residues Pty Ltd, owns mining lease (ML) 3M/2017 located approximately 2.5 km south of the township of Zeehan in western Tasmania. The Dimbulah Copper Gold Project is located directly west of Dimbulah, which covers a total area of over 8,204 hectares.
📊 Share price
$0.04 AUD
Regener8 Resources NL engages in raising seed capital to fund the company’s activities. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-08. The firm operates Kookynie Gold Project (the Project), which comprises one exploration license and eight prospecting licenses located in the Kookynie region in Western Australia’s Goldfields region. The Kookynie Gold Project is located in the northern Goldfields region of Western Australia, covering an area of approximately 15 square kilometers (km2) within the North Coolgardie Mineral Field. The Project is approximately 150 kilometers (km) north of Kalgoorlie and 55km south of Leonora Township, and 50 km northeast of Menzies.
📊 Share price